Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments

M. P. Sormani; M. Rovaris; F. Bagnato; P. Molyneux; P. Bruzzi; C. Pozzilli; D. H. Miller; G. Comi; M. Filippi

Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments

M. P. Sormani, M. Rovaris, F. Bagnato, P. Molyneux, P. Bruzzi, C. Pozzilli, D. H. Miller, G. Comi, M. Filippi

Research output: Contribution to journal › Article › peer-review

Abstract

The authors estimated the sample sizes needed for exploratory trials of MS assessing the efficacy of new treatments in reducing the number of new enhancing lesions vs those of interferon-β or glatiramer acetate. The sample sizes per arm ranged from 868 (effect: 20%) to 94 (effect: 50%) for patients with relapsing-remitting MS and from 2,484 (effect: 20%) to 361 (effect: 50%) for patients with secondary progressive MS. In MS, exploratory trials of new vs available therapies require large numbers of patients, even when MR end-points are used.

Original language	English
Pages (from-to)	1883-1885
Number of pages	3
Journal	Neurology
Volume	57
Issue number	10
Publication status	Published - Nov 27 2001

ASJC Scopus subject areas

Neuroscience(all)

Cite this

@article{a1306eec0fe146ae8024f77055015649,

title = "Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments",

abstract = "The authors estimated the sample sizes needed for exploratory trials of MS assessing the efficacy of new treatments in reducing the number of new enhancing lesions vs those of interferon-β or glatiramer acetate. The sample sizes per arm ranged from 868 (effect: 20%) to 94 (effect: 50%) for patients with relapsing-remitting MS and from 2,484 (effect: 20%) to 361 (effect: 50%) for patients with secondary progressive MS. In MS, exploratory trials of new vs available therapies require large numbers of patients, even when MR end-points are used.",

author = "Sormani, {M. P.} and M. Rovaris and F. Bagnato and P. Molyneux and P. Bruzzi and C. Pozzilli and Miller, {D. H.} and G. Comi and M. Filippi",

year = "2001",

month = nov,

day = "27",

language = "English",

volume = "57",

pages = "1883--1885",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments

AU - Sormani, M. P.

AU - Rovaris, M.

AU - Bagnato, F.

AU - Molyneux, P.

AU - Bruzzi, P.

AU - Pozzilli, C.

AU - Miller, D. H.

AU - Comi, G.

AU - Filippi, M.

PY - 2001/11/27

Y1 - 2001/11/27

N2 - The authors estimated the sample sizes needed for exploratory trials of MS assessing the efficacy of new treatments in reducing the number of new enhancing lesions vs those of interferon-β or glatiramer acetate. The sample sizes per arm ranged from 868 (effect: 20%) to 94 (effect: 50%) for patients with relapsing-remitting MS and from 2,484 (effect: 20%) to 361 (effect: 50%) for patients with secondary progressive MS. In MS, exploratory trials of new vs available therapies require large numbers of patients, even when MR end-points are used.

AB - The authors estimated the sample sizes needed for exploratory trials of MS assessing the efficacy of new treatments in reducing the number of new enhancing lesions vs those of interferon-β or glatiramer acetate. The sample sizes per arm ranged from 868 (effect: 20%) to 94 (effect: 50%) for patients with relapsing-remitting MS and from 2,484 (effect: 20%) to 361 (effect: 50%) for patients with secondary progressive MS. In MS, exploratory trials of new vs available therapies require large numbers of patients, even when MR end-points are used.

UR - http://www.scopus.com/inward/record.url?scp=0035960564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035960564&partnerID=8YFLogxK

M3 - Article

C2 - 11723280

AN - SCOPUS:0035960564

VL - 57

SP - 1883

EP - 1885

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -

Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this